Neuropsychiatric adverse drug reactions and associated factors in a cohort of individuals starting dolutegravir-based or efavirenz-based antiretroviral therapy in Belo Horizonte, Brazil

References

• Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Dec 17]. Available from: https://www.who.int/publications/i/item/9789240031593
   Google Scholar
• Apostolova N, Funes HA, Blas-Garcia A, et al. Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother. 2015;70(10):2693–2708.
   PubMed Web of Science ®Google Scholar
• Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011;15(8):1803–1818.
   PubMed Web of Science ®Google Scholar
• Protocolo clínico e diretrizes terapêuticas Para manejo da infecção pelo HIV em adultos [Internet]. Brasília: Ministério da Saúde; 2018 [citado 2021 Dec 13]. Available from: http://www.aids.gov.br/system/tdf/pub/2016/64484/pcdt_adulto_12_2018_web.pdf?file=1&type=node&id=64484&force=1
   Google Scholar
• Cruciani M, Parisi SG. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and meta-analysis. PLoS One. 2019;14(9):e0222229.
   PubMed Web of Science ®Google Scholar
• Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. Eclinicalmedicine. 2020;28:100573.
   PubMedGoogle Scholar
• Rossetti B, Baldin G, Sterrantino G, et al. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. Antiviral Res. 2019;169:104552.
   PubMed Web of Science ®Google Scholar
• Mendes JC, Ceccato MDGB, Reis AMM, et al. Active pharmacovigilance project on the safety profile of dolutegravir in Brazil. AIDS Care. 2022. DOI:10.1080/09540121.2022.2062289
   Web of Science ®Google Scholar
• Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019;21(1):4–10.
   PubMed Web of Science ®Google Scholar
• Povar-Echeverría M, Comet-Bernad M, Gasso-Sánchez A, et al. Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice. Enferm Infecc Microbiol Clin (Engl Ed). 2021;39(2):78–82.
   PubMedGoogle Scholar
• Fernández-Bargiela N, Rotea-Salvo S, Margusino-Framiñán L, et al. Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. Eur J Hosp Pharm. 2022;29(4):207–211.
   Google Scholar
• Ciccullo A, Borghi V, Giacomelli A, et al. Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding. J Acquir Immune Defic Syndr. 2021;88(3):234–237.
   PubMed Web of Science ®Google Scholar
• Taramasso L, De Vito A, Ricci ED, et al. Durability of dolutegravir-based regimens: a 5-Year prospective observational study. AIDS Patient Care STDS. 2021;35(9):342–353.
   PubMed Web of Science ®Google Scholar
• Hua W, Wang S, Wang X, et al. Neuropsychiatric adverse events during 12 months of treatment with efavirenz in treatment-naïve HIV-infected patients in China: a prospective cohort study. Front Psychiatry. 2021;12:579448.
   PubMed Web of Science ®Google Scholar
• Nasreddine R, Florence E, Vandercam B, et al. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients. AIDS. 2020;34(8):1151–1159.
   PubMed Web of Science ®Google Scholar
• Maintenance and Support Services Organization. Medical dictionary for regulatory activities—MSSO MedDRA. V.24.0 [Internet]; 2021 [cited 2021 Apr 10]. Available from: http://www.meddramsso.com/
   Google Scholar
• Associação Brasileira de Empresas de Pesquisa. Critério de Classificação Econômica Brasil. Brasil: ABEP [Internet]; 2008 [cited 2015 Jan 10]. Available from: http://www.abep.org
   Google Scholar
• de Oliveira-Filho AD, Morisky DE, Neves SJ, et al. The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults. Res Social Adm Pharm. 2014;10(3):554–561.
   PubMed Web of Science ®Google Scholar
• 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1–19.
   Google Scholar
• Botega NJ, Bio MR, Zomignani MA, et al. Transtornos do humor em enfermaria de clínica médica e validação de escala de medida (HADS) de ansiedade e depressão. Rev Saúde Pública. 1995;29(5):359–363.
   Web of Science ®Google Scholar
• Brew BJ, Chan P. Update on HIV dementia and HIV-associated neurocognitive disorders. Curr Neurol Neurosci Rep. 2014;14(8):468.
   PubMed Web of Science ®Google Scholar
• Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder–pathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12(4):234–248.
   PubMed Web of Science ®Google Scholar
• Eggers C, Arendt G, Hahn K, et al. HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol. 2017;264(8):1715–1727.
   PubMed Web of Science ®Google Scholar
• Yombi JC. Dolutegravir neuropsychiatric adverse events: specific drug effect or class effect. AIDS Rev. 2018;20(1):14–26.
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700–708.
   PubMed Web of Science ®Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–935.
   PubMed Web of Science ®Google Scholar
• Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127–e136.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70(5):515–519.
   PubMed Web of Science ®Google Scholar
• Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31(13):1853–1858.
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428–2438.
   PubMed Web of Science ®Google Scholar